FIELD: biotechnology.
SUBSTANCE: following is presented: an anti-CD79b antibody or antigen-binding fragment thereof, a drug conjugate thereof, and their use. The following is also disclosed: a pharmaceutical composition for treating or preventing a disease, a nucleic acid, an expression vector, a cloning vector, a set for treating or preventing a disease mediated by CD79b.
EFFECT: invention makes it possible to use it for the treatment or prevention of a disease mediated by CD79b, as well as in the manufacture of a diagnostic agent for a cell proliferative disorder associated with increased expression of CD79b.
20 cl, 7 dwg, 14 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CD79B ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2817143C2 |
| ANTI-CD79B ANTIBODIES, IMMUNOCONJUGATES AND METHODS FOR THEIR USE | 2019 |
|
RU2791984C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| METHODS FOR USING CD32B x CD79B-BINDING MOLECULES IN TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | 2017 |
|
RU2772434C2 |
| ERIBULIN DERIVATIVE DRUG CONJUGATE, METHOD FOR PREPARATION THEREOF AND USE THEREOF IN MEDICINE | 2021 |
|
RU2830242C1 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| RECOVERED ANTIBODY (VERSIONS), A METHOD FOR PRODUCING THE ANTIBODY, AN ISOLATED NUCLEIC ACID, AN EXPRESSION CASSETTE (VERSIONS), A PLASMID (VERSIONS), A HOST CELL, A PHARMACEUTICAL PREPARATION, A KIT, A METHOD OF TREATING A PATIENT, AT RISK OF OR SUFFERING FROM ESCHERICHIA COLI INFECTION, AND A DIAGNOSTIC TECHNIQUE FOR DETERMINING ESCHERICHIA COLI INFECTIONS | 2014 |
|
RU2724530C2 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC-REGION VARIANTS, AND THEIR APPLICATION METHODS | 2016 |
|
RU2789884C2 |
